The stock of Inozyme Pharma Inc. (NASDAQ:INZY) increased by $0.11 on Friday to finish at $4.93, up 2.28 percent. The last five days have seen an average of 804,400 shares of common stock traded. 20 times new highs were reached in the current year, with a gain of $3.88. The average number of shares traded over the last 20 days was 739,880, while the average volume over the last 50 days totaled 662,780.
INZY stock dropped -18.78% since last month. On 08/02/23, the company’s shares reached a one-month low of $4.68. The stock touched a high of $7.33 on 07/21/23, after rallying from a low of $0.99 in 52 weeks. The price of INZY stock has risen by 369.52% or $3.88 this year, reaching a new high 20 times. Still, the stock price is down -32.74% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
INZY stock investors should be aware that Inozyme Pharma Inc. (INZY) stock had its last reported insider trading activity 13 days ago on Aug 01. On Aug 01, Director Hopfner Robert Lorne acquired 833,333 shares at $4.80 each. This transaction resulted in the insider spending $3,999,998. On Aug 01, Pivotal bioVenture Partners Fu added 833,333 shares at a price of US$4.80. After the transaction, the insider now owns 2,923,110 shares. Director Hopfner Robert Lorne had earlier bought 228,702 shares on May 12 for $6.25 a share. The transaction was completed for $1,429,388.
Financial Health
For the three months ended June 29, Inozyme Pharma Inc.’s quick ratio was 11.90, while its current ratio was 11.90, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.30, and the total debt to equity ratio is 0.30.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. INZY’s return on assets (ROA) during the last 12 months has been -46.40%. In the meantime, the return on equity (ROE) for the last 12 months was -58.80%.
Earnings Surprise
According to Inozyme Pharma Inc.’s quarterly financial report for the quarter that ended June 29, it had $31.88 million in total debt versus $99.4 million in cash and short-term investments. It was predicted that Inozyme Pharma Inc.’s quarterly earnings would be -$0.35, but it ended up being -$0.43, beating the consensus by 18.60%. At the end of Inozyme Pharma Inc.’s most recent quarter ended June 29, its liabilities totaled 45.34 million, while its total debt was $34.12 million. Equity owned by shareholders amounts to $61.73 million.
Technical Picture
Here’s a quick look at Inozyme Pharma Inc.’s (INZY) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 40.94%, suggesting the stock is Neutral, with a 55.85% historical volatility rate.
The stochastic %K and %D were 9.57% and 8.68% respectively, while the average true range (ATR) was 0.38. Based on the 14-day stochastic reading of 14.37%, the RSI (14) reading is 41.46%. On the 9-day MACD Oscillator, the stock is at -0.01, and the 14-day reading is at -0.18.
Analyst Ratings
In its most recent analyst report, Jefferies raised its rating on Inozyme Pharma Inc. (NASDAQ: INZY) to a Buy. Prior to this, analysts firm rated the stock as a Hold.
